Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Virology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Minireviews
    • JVI Classic Spotlights
    • Archive
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JVI
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Virus-Cell Interactions

CD147/EMMPRIN Acts as a Functional Entry Receptor for Measles Virus on Epithelial Cells

Akira Watanabe, Misako Yoneda, Fusako Ikeda, Yuri Terao-Muto, Hiroki Sato, Chieko Kai
Akira Watanabe
2International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Misako Yoneda
1Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fusako Ikeda
1Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuri Terao-Muto
2International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroki Sato
1Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chieko Kai
1Laboratory Animal Research Center, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
2International Research Center for Infectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ckai@ims.u-tokyo.ac.jp
DOI: 10.1128/JVI.02168-09
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIG. 1.
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    CypA and CypB are identified as MeV-N-interacting proteins by proteomic analysis. The C-terminal region of MeV-N, which is usually called the tail region, was used as a bait protein, and N_TAIL-binding proteins were pulled down from the COBL-a cell lysate. The binding proteins were trypsinized in solution without separation by SDS-PAGE and were subjected to MALDI-TOF MS. Detected ions were analyzed using the Mascot search engine. Amino acid sequences of CypA (A) and CypB (B) are shown. Peptides detected by MALDI-TOF MS are exhibited in red. Scores for each ion from CypA (C) and CypB (D) are shown, and individual ion scores of >36 indicate identity and extensive homology.

  • FIG. 2.
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    GST pull-down and coimmunoprecipitation (IP) assays showing direct binding of CypA and CypB to MeV-N. We incubated 2 μg of His-tagged MeV-N with 2 μg of GST-CypA (A), GST-CypB (B), or GST (A) for 30 min on ice, and then glutathione-Sepharose beads were added to each sample. After washing of the beads, trapped proteins were analyzed by SDS-PAGE followed by Western blotting (WB). To detect MeV-N, anti-His6 antibody was used as the primary antibody. For assays using CsA, a 5 μM final concentration was used for CypA and 5, 15, and 30 μM final concentrations were used for CypB. The numbers in the figure show the final concentration of CsA in each sample. (C) We incubated 2 μg of His-tagged MeV-N or His-tagged ENO1 with 2 μg of GST-CypA or GST-CypB. GST pull-down assays were performed according to the procedure described above. (D and E) We transiently transfected 1 μg of pCMV-myc-MeV-N with 1 μg of pCMV-HA-CypA (E) or pCMV-HA-CypB (D) into HEK293 cells (1.5 × 106 cells). At 24 h posttransfection, the cells were lysed, and 0.5 μg of anti-myc monoclonal antibody and protein G Sepharose beads were added to the lysate. After washing of the beads, trapped proteins were analyzed by SDS-PAGE followed by Western blotting with anti-myc or anti-HA polyclonal antibody.

  • FIG. 3.
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Evidence of incorporation of CypA and CypB into MeV particles. Culture medium of MeV-infected B95a cells was ultracentrifuged to pellet down the virus. The resultant pellet was resuspended with TN buffer and placed on a 20% to 60% sucrose layer (the volume of each sucrose layer was 1 ml). After ultracentrifugation, 600-μl fractions were collected sequentially from the bottom of the tube in the case of MeV-HL. (A) CypA, CypB, and MeV-N in each fraction of MeV-HL were detected by Western blotting. (B) The virus titer of each fraction was estimated using B95a cells. The virus titer and relative amounts of CypA, CypB, and MeV-N in each fraction of MeV-HL were graphed. (C) Trichloroacetic acid was added to fraction 2, and the resultant pellet was analyzed by SDS-PAGE and Coomassie brilliant blue staining. MeV-infected or mock-infected B95a cells were lysed with PBS containing 0.5% NP-40, and the cell lysates were placed on a 20% to 60% sucrose layer (the volume of each sucrose layer was 1 ml). After ultracentrifugation, 600-μl fractions were collected sequentially from the bottom of the tube. CypA, CypB, and MeV-N in each fraction of the MeV-infected cell lysate (D) and CypA and CypB in each fraction of the mock-infected cell lysate (E) were detected by Western blotting.

  • FIG. 4.
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    Incorporation of CypA or CypB into MeV. (A) MeV-HL, MeV-EGFP, and MeV-luc were purified by sucrose density gradient centrifugation. Virus particles were developed by SDS-PAGE and analyzed by Western blotting with anti-MeV-N, -CypA, and -CypB antibodies. (B) B95a cells were infected with MeV-luc at an MOI of 0.2. At 18 hpi, the cytoplasmic fraction of infected cells was extracted with hypotonic buffer. CypA, CypB, and MeV-N in the cytoplasmic fraction were detected by Western blotting. As a control, mock-infected B95a cells were used. (C and D) Localization of cyclophilins and MeV-N in MeV-luc-infected B95a cells was examined by immunofluorescence staining. CypB (C) and CypA (D) distributions (green; left panels), MeV-N distribution (red; second panels), their overlay (third panels), and phase-contrast images (right panels) are shown in striatal sections. Each panel represents sequential confocal scans of the same field. Arrows in the left panel indicate uninfected cells.

  • FIG. 5.
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    Effect of CsA treatment on MeV infectivity to epithelial cells. MeV-luc was propagated with and without 5 μg/ml CsA, and then the culture medium of infected cells was ultracentrifuged to pellet down viruses. The resultant pellets were rinsed and resuspended with fresh medium. The virus propagated without CsA was named MeV-luc (−), and that propagated with CsA was named MeV-luc (+). MeV-luc (−) and MeV-luc (+) were titrated using B95a cells. HEK293-SLAM cells (A) and HEK293 cells (B) were infected with the viruses at an MOI of 1.0. At 24 hpi, the luciferase activity of infected cells was measured. The white and black bars represent the infectivities of MeV-luc (−) and MeV-luc (+), respectively. Luciferase assays were performed in triplicate. Data are means plus standard errors of the means (SEM). *, P = 0.003 (Student's t test). (C) MeV-luc (−) and MeV-luc (+) were further purified by sucrose gradient density centrifugation and were analyzed by Western blotting with anti-MeV-N, -CypA, and -CypB antibodies. (D) HEK293 cells (6 × 104 cells) were preincubated with 0, 30, or 60 μg/ml of recombinant CypB for 30 min at room temperature and then infected with MeV-luc at an MOI of 1.0 in the presence of 0, 30, or 60 μg/ml of recombinant CypB at 37°C for another hour. After incubation, cells were washed three times with medium containing fusion block peptide to stop infection and to remove viruses and recombinant CypB. The luciferase activity of infected cells was measured at 24 hpi. Luciferase assays were performed in triplicate. Data are means plus SEM. *, P = 0.0007 (Student's t test).

  • FIG. 6.
    • Open in new tab
    • Download powerpoint
    FIG. 6.

    Contribution of CD147 to MeV infection of epithelial cells. (A) HEK293 cells (1 × 106 cells) were incubated with 1 μg of anti-CD147, -CD36, -CD46, or -SLAM mouse monoclonal antibody for 1 hour. After being washed, cells were incubated with 0.5 μl of Alexa Fluor 468-conjugated goat anti-mouse IgG polyclonal antibody for 1 hour. After being washed, cells were analyzed by flow cytometry. (B) HEK293 cells (6 × 104 cells) were preincubated with 50 μg/ml of anti-CD147, -CD36, or -CD46 antibody for 30 min at room temperature and then infected with MeV-luc at an MOI of 1.0 in the presence of 50 μg/ml of each antibody at 37°C for another hour. After incubation, cells were washed three times with medium containing fusion block peptide to stop infection and to remove viruses and antibodies. The luciferase activity of infected cells was measured at 24 hpi. Luciferase assays were performed in triplicate. Data are means plus SEM. *, P = 0.020 (Student's t test).

  • FIG. 7.
    • Open in new tab
    • Download powerpoint
    FIG. 7.

    Effect of overexpression of CD147 on MeV infection in CHO-K1 cells. (A) Expression of human CD147 on CHO/CD147 cells was confirmed by flow cytometry with anti-human CD147 antibody. (B) CHO/CD147 and CHO/pCAG cells (3 × 104 cells each) were incubated with MeV-EGFP at an MOI of 4.0 at 37°C for 1 hour. The MOI corresponded to that estimated for B95a cells. After the incubation, cells were washed three times with medium containing fusion block peptide. At 48 hpi, cells were observed by confocal fluorescence microscopy. (C) CHO/CD147 and CHO/pCAG cells (3 × 104 cells each) were incubated with MeV-EGFP at an MOI of 1.0 at 37°C for 1 hour. After incubation, the cells were washed thrice with a medium containing fusion block peptide. At 48 hpi, we counted the number of GFP-positive cells by using a confocal fluorescence microscope. Data are means plus SEM. *, P = 0.0004 (Student's t test). (D) CHO/CD147 and CHO/pCAG cells (3 × 104 cells each) were incubated with MeV-luc at an MOI of 4.0 at 37°C for 1 hour. After the incubation, cells were washed three times with medium containing fusion block peptide. The luciferase activity of infected cells was measured at 48 hpi. The white and black bars represent the infectivities to CHO/pCAG and CHO/CD147 cells, respectively. Luciferase assays were performed in triplicate. Data are means plus SEM. *, P = 0.022 (Student's t test). (E) CHO/CD147 and CHO/pCAG cells (3 × 104 cells each) were incubated with MeV-luc in the presence of anti-CD147 antibody at an MOI of 4.0 at 37°C for 30 min. After the incubation, cells were washed three times with medium containing fusion block peptide. The luciferase activity of infected cells was measured at 48 hpi. The white and black bars represent the infectivities to CHO/pCAG and CHO/CD147 cells, respectively. (−), infection without antibody, as a negative control; (+), infection with anti-CD147 antibody. Luciferase assays were performed in triplicate. Data are means plus SEM. **, P = 0.035 (Student's t test).

PreviousNext
Back to top
Download PDF
Citation Tools
CD147/EMMPRIN Acts as a Functional Entry Receptor for Measles Virus on Epithelial Cells
Akira Watanabe, Misako Yoneda, Fusako Ikeda, Yuri Terao-Muto, Hiroki Sato, Chieko Kai
Journal of Virology Apr 2010, 84 (9) 4183-4193; DOI: 10.1128/JVI.02168-09

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Virology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
CD147/EMMPRIN Acts as a Functional Entry Receptor for Measles Virus on Epithelial Cells
(Your Name) has forwarded a page to you from Journal of Virology
(Your Name) thought you would be interested in this article in Journal of Virology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
CD147/EMMPRIN Acts as a Functional Entry Receptor for Measles Virus on Epithelial Cells
Akira Watanabe, Misako Yoneda, Fusako Ikeda, Yuri Terao-Muto, Hiroki Sato, Chieko Kai
Journal of Virology Apr 2010, 84 (9) 4183-4193; DOI: 10.1128/JVI.02168-09
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Basigin
epithelial cells
measles virus
Receptors, Virus
Virus Internalization

Related Articles

Cited By...

About

  • About JVI
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #Jvirology

@ASMicrobiology

       

 

JVI in collaboration with

American Society for Virology

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0022-538X; Online ISSN: 1098-5514